BridgeBio Pharma is a Biotech Stock With Strong Potential Thanks to an Innovative Approach in Precision Medicine. Redburn Atlantic Sees Over 40% Upside Potential.
Reading Time: 2 minutes
The biotech stock of BridgeBio Pharma (BBIO) has held up remarkably well in recent weeks. BridgeBio Pharma's business model is based on an innovative approach to developing precision medicine for rare genetic diseases. Last November, BridgeBio Pharma announced FDA approval for Attruby (Acoramidis). Attruby is an orally administered, nearly complete transthyretin (TTR) stabilizer (≥90%) developed for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval is based on the results of the Phase 3 ATTRibute-CM study,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
